Cargando…

Safety profile of gadoxetate disodium in elderly patients (≥65 years)

BACKGROUND: Safety data on routine clinical use of gadoxetate disodium in elderly patients is not reported yet. PURPOSE: To assess the safety of liver specific gadoxetate disodium in contrast enhanced magnetic resonance imaging in elderly patients (≥65 years) in comparison to adults (18–64 years). M...

Descripción completa

Detalles Bibliográficos
Autores principales: Endrikat, Jan, Schwenke, Carsten, Vogtlaender, Kai, Dohannish, Susan, Breuer, Josy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751856/
https://www.ncbi.nlm.nih.gov/pubmed/28372493
http://dx.doi.org/10.1177/0284185117700673
_version_ 1783290034690981888
author Endrikat, Jan
Schwenke, Carsten
Vogtlaender, Kai
Dohannish, Susan
Breuer, Josy
author_facet Endrikat, Jan
Schwenke, Carsten
Vogtlaender, Kai
Dohannish, Susan
Breuer, Josy
author_sort Endrikat, Jan
collection PubMed
description BACKGROUND: Safety data on routine clinical use of gadoxetate disodium in elderly patients is not reported yet. PURPOSE: To assess the safety of liver specific gadoxetate disodium in contrast enhanced magnetic resonance imaging in elderly patients (≥65 years) in comparison to adults (18–64 years). MATERIAL AND METHODS: Safety data on gadoxetate disodium were analyzed from 12 clinical phase II–III studies and from our pharmacovigilance database. A comparison between elderly (≥65 years) versus adults (18–64 years) was performed with respect to the frequency of drug-related adverse events (AEs) in clinical phase II–III studies and adverse drug reactions (ADRs) in the pharmacovigilance database. RESULTS: In clinical studies, 1989 patients were enrolled: 675 elderly and 1314 adults. Twenty-three elderly patients (3.4%) suffered at least one drug-related AE in contrast to 58 patients (4.4%) in the group of adults (odds ratio = 0.76; 95% confidence interval = 0.45–1.27). Since marketing authorization in 2004, more than 3.5 million patients have been exposed to gadoxetate disodium worldwide: 1.7 million (48.6%) in elderly and 1.8 million (51.4%) in adults. The number of patients with post-marketing ADRs (total n = 793) was 354 (0.021%) in the elderly group and 439 (0.024%) in the adult group. Thus, there were significantly fewer patients with ADRs reported in the group of elderly versus adults (P = 0.028). Hypersensitivity/immune system disorders, gastrointestinal disorders, and respiratory disorders were the most frequent ADRs in both groups, elderly and adults. CONCLUSION: The incidence of drug-related AEs in clinical studies was similar and that of patients with ADRs in the post-marketing setting was lower in elderly (≥65 years) compared with younger adults aged 18–64 years. Overall, gadoxetate disodium shows a favorable safety profile in both age groups.
format Online
Article
Text
id pubmed-5751856
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-57518562018-01-29 Safety profile of gadoxetate disodium in elderly patients (≥65 years) Endrikat, Jan Schwenke, Carsten Vogtlaender, Kai Dohannish, Susan Breuer, Josy Acta Radiol Contrast Media BACKGROUND: Safety data on routine clinical use of gadoxetate disodium in elderly patients is not reported yet. PURPOSE: To assess the safety of liver specific gadoxetate disodium in contrast enhanced magnetic resonance imaging in elderly patients (≥65 years) in comparison to adults (18–64 years). MATERIAL AND METHODS: Safety data on gadoxetate disodium were analyzed from 12 clinical phase II–III studies and from our pharmacovigilance database. A comparison between elderly (≥65 years) versus adults (18–64 years) was performed with respect to the frequency of drug-related adverse events (AEs) in clinical phase II–III studies and adverse drug reactions (ADRs) in the pharmacovigilance database. RESULTS: In clinical studies, 1989 patients were enrolled: 675 elderly and 1314 adults. Twenty-three elderly patients (3.4%) suffered at least one drug-related AE in contrast to 58 patients (4.4%) in the group of adults (odds ratio = 0.76; 95% confidence interval = 0.45–1.27). Since marketing authorization in 2004, more than 3.5 million patients have been exposed to gadoxetate disodium worldwide: 1.7 million (48.6%) in elderly and 1.8 million (51.4%) in adults. The number of patients with post-marketing ADRs (total n = 793) was 354 (0.021%) in the elderly group and 439 (0.024%) in the adult group. Thus, there were significantly fewer patients with ADRs reported in the group of elderly versus adults (P = 0.028). Hypersensitivity/immune system disorders, gastrointestinal disorders, and respiratory disorders were the most frequent ADRs in both groups, elderly and adults. CONCLUSION: The incidence of drug-related AEs in clinical studies was similar and that of patients with ADRs in the post-marketing setting was lower in elderly (≥65 years) compared with younger adults aged 18–64 years. Overall, gadoxetate disodium shows a favorable safety profile in both age groups. SAGE Publications 2017-04-03 2018-01 /pmc/articles/PMC5751856/ /pubmed/28372493 http://dx.doi.org/10.1177/0284185117700673 Text en © The Foundation Acta Radiologica 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Contrast Media
Endrikat, Jan
Schwenke, Carsten
Vogtlaender, Kai
Dohannish, Susan
Breuer, Josy
Safety profile of gadoxetate disodium in elderly patients (≥65 years)
title Safety profile of gadoxetate disodium in elderly patients (≥65 years)
title_full Safety profile of gadoxetate disodium in elderly patients (≥65 years)
title_fullStr Safety profile of gadoxetate disodium in elderly patients (≥65 years)
title_full_unstemmed Safety profile of gadoxetate disodium in elderly patients (≥65 years)
title_short Safety profile of gadoxetate disodium in elderly patients (≥65 years)
title_sort safety profile of gadoxetate disodium in elderly patients (≥65 years)
topic Contrast Media
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751856/
https://www.ncbi.nlm.nih.gov/pubmed/28372493
http://dx.doi.org/10.1177/0284185117700673
work_keys_str_mv AT endrikatjan safetyprofileofgadoxetatedisodiuminelderlypatients65years
AT schwenkecarsten safetyprofileofgadoxetatedisodiuminelderlypatients65years
AT vogtlaenderkai safetyprofileofgadoxetatedisodiuminelderlypatients65years
AT dohannishsusan safetyprofileofgadoxetatedisodiuminelderlypatients65years
AT breuerjosy safetyprofileofgadoxetatedisodiuminelderlypatients65years